Graybug and CalciMedica Enter into Definitive Merger Agreement
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 Phase 2b results in acute pancreatitis for …
Graybug and CalciMedica Enter into Definitive Merger Agreement Read More »